Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375408" target="_blank" >RIV/00216208:11130/18:10375408 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/18:10375408

Výsledek na webu

<a href="https://doi.org/10.1007/s00259-017-3829-7" target="_blank" >https://doi.org/10.1007/s00259-017-3829-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00259-017-3829-7" target="_blank" >10.1007/s00259-017-3829-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

Popis výsledku v původním jazyce

Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0-6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of &lt;= 3 was the most useful predictor across trials. A SIOPEN score &lt;= 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores &lt;= 3 were 47% +/- 7% versus 26% +/- 3% for higher scores at diagnosis (p &lt; 0.007) and 36% +/- 4% versus 14% +/- 4% (p &lt; 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores &lt;= 3 of 51% +/- 7% versus 34% +/- 4% for higher scores (p &lt; 0.001) at diagnosis and 43% +/- 5% versus 16% +/- 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores &lt;= 3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score &gt; 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.

Název v anglickém jazyce

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

Popis výsledku anglicky

Background Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. Results The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0-6 scale in 12 anatomical regions. Evaluable mIBG scans from 216 COG-A3973 and 341 SIOPEN/HR-NBL1 trial patients were reviewed pre- and post-induction chemotherapy. The prognostic value of skeletal scores for 5-year event free survival (5 yr.-EFS) was tested in the source and validation cohorts. At diagnosis, both cohorts showed a gradual non-linear increase in risk with cumulative scores. Several approaches were explored to test the relationship between score and EFS. Ultimately, a cutoff score of &lt;= 3 was the most useful predictor across trials. A SIOPEN score &lt;= 3 pre-induction was found in 15% SIOPEN patients and in 22% of COG patients and increased post-induction to 60% in SIOPEN patients and to 73% in COG patients. Baseline 5 yr.-EFS rates in the SIOPEN/HR-NBL1 cohort for scores &lt;= 3 were 47% +/- 7% versus 26% +/- 3% for higher scores at diagnosis (p &lt; 0.007) and 36% +/- 4% versus 14% +/- 4% (p &lt; 0.001) for scores obtained post-induction. The COG-A3973 showed 5 yr.-EFS rates for scores &lt;= 3 of 51% +/- 7% versus 34% +/- 4% for higher scores (p &lt; 0.001) at diagnosis and 43% +/- 5% versus 16% +/- 6% (p = 0.004) for post-induction scores. Hazard ratios (HR) significantly favoured patients with scores &lt;= 3 after adjustment for age and MYCN-amplification. Optimal outcomes were recorded in patients who achieved complete skeletal response. Conclusions Validation in two independent cohorts confirms the prognostic value of the SIOPEN skeletal score. In particular, patients with an absolute SIOPEN score &gt; 3 after induction have very poor outcomes and should be considered for alternative therapeutic strategies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Nuclear Medicine &amp; Molecular Imaging

ISSN

1619-7070

e-ISSN

—

Svazek periodika

45

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

14

Strana od-do

292-305

Kód UT WoS článku

000418963400017

EID výsledku v databázi Scopus

2-s2.0-85029741165